Company Filing History:
8 out of 403 
2 out of 3,688 
1 out of 832,912 Years Active: 2016-2025
Title: Innovations by Devanand Sarkar: Advancements in Cancer Treatment
Introduction
Devanand Sarkar, an inventor based in Richmond, VA, has made significant contributions to the field of oncology through his inventive work. With a record of 8 patents, Sarkar's research focuses on the development of innovative therapeutic approaches to treat various forms of cancer.
Latest Patents
Among his notable inventions is the tropism modified cancer terminator virus, specifically Ad.5/3 CTV and Ad.5/3-CTV-M7. This innovative virus has been proven to exhibit infectivity that is independent of the Coxsackie Adenoviral Receptor (CAR). The Ad.5/3-CTV can be utilized alone or in conjunction with other therapeutic agents, including those that enhance reactive oxygen species (ROS) production, HDAC inhibitors, MCL-1 inhibitors, and Bcl-2 inhibitors. This versatility allows it to target a variety of cancers, emphasizing treatments for malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.
Career Highlights
Sarkar's career has included significant roles at esteemed institutions such as Virginia Commonwealth University and The Johns Hopkins University. His expertise and dedication to cancer research have positioned him at the forefront of innovative therapeutic strategies.
Collaborations
Throughout his career, Devanand Sarkar has collaborated with notable individuals including Paul B. Fisher and Swadesh K. Das. These collaborations have further enhanced the research output and the impact of his inventions, facilitating advancements in cancer treatment methodologies.
Conclusion
Devanand Sarkar continues to make strides in cancer research through his innovative inventions, particularly in the area of modified viral therapies. His work not only showcases his creativity and commitment to science but also holds great promise for future advancements in cancer treatments.